Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 4.

Journal Article

Davids, Matthew S., Hallek, Michael, Wierda, William, Roberts, Andrew W., Stilgenbauer, Stephan, Jones, Jeffrey A., Gerecitano, John F., Kim, Su Young, Potluri, Jalaja, Busman, Todd, Best, Andrea, Verdugo, Maria E., Cerri, Elisa, Desai, Monali, Hillmen, Peter and Seymour, John F. (2018). Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin. Cancer Res., 24 (18). S. 4371 - 4380. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Davids, Matthew Steven, Seymour, John Francis, Roberts, Andrew Warwick, Eichhorst, Barbara, Kipps, Thomas J., Mato, Anthony R., Stilgenbauer, Stephan, Mobasher, Mehrdad, Desai, Monali Bhardwaj, Potluri, Jalaja, Pena, German E., Verdugo, Maria E., Nielsen, Jacqueline, Cyr, Aimee, Fleming, Leanne Lash and Hallek, Michael J. (2018). Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kater, Arnon P., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Kipps, Thomas J., Owen, Carolyn, Boyer, Michelle, Humphrey, Kathryn, Punnoose, Elizabeth A., Wang, Jue, Chyla, Brenda, Verdugo, Maria E., Wu, Jenny, Jiang, Yanwen, Mobasher, Mehrdad and Seymour, John F. (2018). First Prospective Data on Impact of Minimal Residual Disease on Long - Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Lamanna, Nicole, Verdugo, Maria E., Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad and Kater, Arnon P. (2018). MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Oct 22 05:38:58 2021 CEST.